Keros Therapeutics Q4 net loss narrows to $23.5 mln

Keros Therapeutics

04/03/2026 21:12

Overview

Biopharmaceutical firm reported narrowed Q4 net loss of $23.5 mln

Company reported FY net income of $87 mln for 2025, aided by Takeda license revenue

Keros plans Phase 2 trials for rinvatercept in DMD and ALS in 2026

Outlook

Keros expects to start Phase 2 trial for DMD in Q2 2026

Company plans to engage regulators for ALS trial design in H2 2026

Keros expects cash to fund operations into H1 2028

Result Drivers

TAKEDA LICENSE REVENUE - Net income for 2025 was largely driven by revenue from Keros' license agreement with Takeda

R&D EXPENSE DECREASE - Transition of elritercept-related R&D expenses to Takeda led to lower expenses

G&A EXPENSE INCREASE - Higher external costs led to increased general and administrative expenses despite reduced headcount

Company press release: ID:nGNXc43Xsd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$23.46 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Keros Therapeutics Inc is $23.00, about 71.6% above its March 3 closing price of $13.40

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)